Michael Rowe Biography and Net Worth

COO of Hyperion DeFi

Michael Rowe has been serving as our Vice President, Commercial since October 2019 and, prior to that, since July 2018, as our Vice President, Marketing. From February 2016 to June 2018, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization, planning and execution for Rhopressa®, for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Previously, he spent 12 years at Allergan plc (NYSE: AGN) in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort® UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First HealthCare, Inc. (a former public company) and Pfizer Inc (NYSE: PFE). Mr. Rowe holds an M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.

What is Michael M. Rowe's net worth?: The estimated net worth of Michael M. Rowe is at least $5.45 thousand as of August 28th, 2024. Mr. Rowe owns 1,374 shares of Hyperion DeFi stock worth more than $5,455 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Rowe may own. Additionally, Mr. Rowe receives an annual salary of $775,470.00 as COO at Hyperion DeFi. Learn More about Michael M. Rowe's net worth.
How old is Michael M. Rowe?: Mr. Rowe is currently 62 years old. There are 3 older executives and no younger executives at Hyperion DeFi. Learn More on Michael M. Rowe's age.
What is Michael M. Rowe's salary?: As the COO of Hyperion DeFi, Inc., Mr. Rowe earns $775,470.00 per year. Learn More on Michael M. Rowe's salary.
How do I contact Michael M. Rowe?: The corporate mailing address for Mr. Rowe and other Hyperion DeFi executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Hyperion DeFi can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Michael M. Rowe's contact information.
Has Michael M. Rowe been buying or selling shares of Hyperion DeFi?: Michael M. Rowe has not been actively trading shares of Hyperion DeFi in the last ninety days. Most recently, on Wednesday, August 28th, Michael M. Rowe bought 338 shares of Hyperion DeFi stock. The stock was acquired at an average cost of $41.60 per share, with a total value of $14,060.80. Following the completion of the transaction, the chief executive officer now directly owns 1,374 shares of the company's stock, valued at $57,158.40. Learn More on Michael M. Rowe's trading history.
Who are Hyperion DeFi's active insiders?: Hyperion DeFi's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Hyperion DeFi's active insiders.

Michael M. Rowe Insider Trading History at Hyperion DeFi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/28/2024	Buy	338	$41.60	$14,060.80	1,374
8/26/2024	Buy	625	$45.60	$28,500.00	1,036
12/4/2023	Buy	61	$108.80	$6,636.80	411
9/19/2023	Buy	17	$132.80	$2,257.60	350
9/15/2023	Buy	14	$140.00	$1,960.00	332
10/27/2021	Buy	15	$331.20	$4,968.00
9/13/2021	Buy	18	$352.00	$6,336.00	53
5/27/2021	Buy	17	$376.80	$6,405.60	35
9/25/2018	Buy	10	$338.40	$3,384.00

Michael M. Rowe Buying and Selling Activity at Hyperion DeFi

Hyperion DeFi Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $3.97

$3.50

$4.09

50 Day Range

MA: $6.70

$3.61

$11.83

2 Week Range

Now: $3.97

$0.85

$17.99

Volume

408,169 shs

Average Volume

328,192 shs

Market Capitalization

$32.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Michael Rowe Biography and Net Worth

What is Michael M. Rowe's net worth?

How old is Michael M. Rowe?

What is Michael M. Rowe's salary?

How do I contact Michael M. Rowe?

Has Michael M. Rowe been buying or selling shares of Hyperion DeFi?

Who are Hyperion DeFi's active insiders?